These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33275060)

  • 1. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
    Geng C; Yang G; Wang H; Wu Y; Leng Y; Zhou H; Zhang Z; Jian Y; Chen W
    Leuk Lymphoma; 2021 Apr; 62(4):883-890. PubMed ID: 33275060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Frølund UC; Andersen KT; Klostergaard A; Helleberg C; Pedersen RS; Pedersen PT; Helm-Petersen S; Teodorescu EM; Preiss B; Abildgaard N; Gimsing P;
    PLoS One; 2017; 12(12):e0188988. PubMed ID: 29216227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
    Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
    Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis.
    Chen Y; Chen Z; Cao J; Lin L; Li J
    Hematology; 2024 Dec; 29(1):2329378. PubMed ID: 38470208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.
    Heaney JLJ; Campbell JP; Iqbal G; Cairns D; Richter A; Child JA; Gregory W; Jackson G; Kaiser M; Owen R; Davies F; Morgan G; Dunn J; Drayson MT
    Leukemia; 2018 Aug; 32(8):1727-1738. PubMed ID: 29925902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma.
    Chakraborty R; Rybicki L; Nakashima MO; Dean RM; Faiman BM; Samaras CJ; Rosko N; Dysert H; Valent J; Anwer F
    Br J Haematol; 2020 Jun; 189(6):1074-1082. PubMed ID: 32108328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].
    Yin JH; Xu TT; Wang Y; Chen WM; Liu AJ
    Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1152-1157. PubMed ID: 36207970
    [No Abstract]   [Full Text] [Related]  

  • 8. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.
    Dávila J; González-Calle V; Escalante F; Cerdá S; Puig N; García-Sanz R; Bárez A; Montes C; López R; Alonso JM; Aguilar C; García-Mateo A; Labrador J; Aguilera C; García-Coca A; Hernández R; Mateos MV; Ocio EM
    Br J Haematol; 2022 Jul; 198(2):278-287. PubMed ID: 35383901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma.
    Huang W; Wei X; Wei Q; Wei Y; Feng R
    Transl Cancer Res; 2021 Dec; 10(12):5258-5266. PubMed ID: 35116375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation.
    Gao W; Li J; Wu Y; Li Y; Leng Y; Liu A; Yang G; Tian Y; Wang H; Wang G; Wu Z; Ren Z; Chen W
    Ann Hematol; 2019 May; 98(5):1177-1184. PubMed ID: 30610278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.
    Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
    Clin Exp Med; 2023 Oct; 23(6):2593-2600. PubMed ID: 36703087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
    Geng C; Yang G; Wang H; Zhang Z; Zhou H; Chen W
    Biomed Res Int; 2021; 2021():6689457. PubMed ID: 34104651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.
    Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Kourelis TV; Gonsalves W; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar SV; Gertz MA
    Leukemia; 2017 Jan; 31(1):92-99. PubMed ID: 27211265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
    Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
    Hematology; 2023 Dec; 28(1):2161222. PubMed ID: 36607148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.
    Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Tay J; Bahlis N
    Leuk Lymphoma; 2018 Aug; 59(8):1920-1926. PubMed ID: 29160734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma.
    Caro J; Cairns D; Menzies T; Boyle E; Pawlyn C; Cook G; Kaiser M; Walker BA; Owen R; Jackson GH; Morgan GJ; Heaney J; Drayson MT; Davies FE
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e279-e284. PubMed ID: 34876373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
    Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
    Lakhwani S; Rosiñol L; Puig N; Pico-Picos MA; Medina-González L; Martínez-López J; Paiva B; Cedena MT; Oriol A; Ríos-Tamayo R; Blanchard MJ; Jarque I; Bargay J; Moraleda JM; Carrillo-Cruz E; Sureda A; Krsnik I; González E; Casado LF; Martí JM; Encinas C; De Arriba F; Palomera L; Sampol A; González-Montes Y; Motlló C; De La Cruz J; Alonso R; Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J; Hernández MT
    Haematologica; 2024 Jun; 109(6):1909-1917. PubMed ID: 38031761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.
    Eisfeld C; Eßeling E; Wullenkord R; Khandanpour C; Reusch J; Mikesch JH; Reicherts C; Kerkhoff A; Schliemann C; Kessler T; Mesters RM; Berdel WE; Lenz G; Stelljes M
    Ann Hematol; 2020 Aug; 99(8):1907-1915. PubMed ID: 32444892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
    Muchtar E; Magen H; Itchaki G; Cohen A; Rosenfeld R; Shochat T; Kornowski R; Iakobishvili Z; Raanani P
    Leuk Res; 2016 Feb; 41():56-61. PubMed ID: 26658109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.